MorphoSys AG Initiates Phase 2 Study of Anti-CD19 Antibody MOR208 in Non- Hodgkin's Lymphoma
5/13/2013 11:47:11 AM
More...
|
MorphoSys AG Announces First Scientific Publication on Novel Antibody Platform Ylanthia
5/10/2013 10:43:38 AM
More...
|
MorphoSys AG Reports Results for the First Quarter of 2013
5/3/2013 10:55:11 AM
More...
|
MorphoSys AG Initiates Phase 2 Study of Anti-CD19 Antibody MOR208 in B-cell Acute Lymphoblastic Leukemia
4/26/2013 9:56:15 AM
More...
|
MorphoSys AG to Host Q1 2013 Conference Call on May 3, 2013
4/26/2013 9:54:38 AM
More...
|
MorphoSys AG to Start Share Buy-Back Program
4/22/2013 12:20:55 PM
More...
|
MorphoSys AG to Present at Kempen & Co's Life Sciences & Healthcare Conference
4/22/2013 12:16:07 PM
More...
|
MorphoSys AG: Announcement of the Convening of the AGM in Munich/Germany on 4 June 2013 According to Sec. 121 Para. 4a AktG With the Objective of Europe-Wide Distribution
4/16/2013 10:25:03 AM
More...
|
MorphoSys AG: Publication Pursuant to SS Sect.1 WpHG (the German Securities Trading Act) With the Aim of Pan-European Distribution
3/13/2013 8:23:43 AM
More...
|
MorphoSys AG Reports Results for Fiscal Year 2012
3/5/2013 9:23:30 AM
More...
|
|